OXLUMO

This brand name is authorized in Austria, Brazil, Croatia, Estonia, France, Ireland, Israel, Italy, Lithuania, Poland, Romania, Spain, UK.

Active ingredients

The drug OXLUMO contains one active pharmaceutical ingredient (API):

1	Lumasiran UNII 67P6XH37HD - LUMASIRAN SODIUM
	Lumasiran is a double-stranded small interfering ribonucleic acid (siRNA) that reduces levels of glycolate oxidase (GO). Decreased GO enzyme levels reduce the amount of available glyoxylate, a substrate for oxalate production. This results in reduction of urinary and plasma oxalate levels, the underlying cause of disease manifestations in patients with primary hyperoxaluria type 1 (PH1).
	Read more about Lumasiran

Medication package inserts

Below package inserts are available for further reading:

Document	Type	Information Source
OXLUMO Solution for injection	MPI, EU: SmPC	European Medicines Agency (EU)

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
A16AX18		A Alimentary tract and metabolism → A16 Other alimentary tract and metabolism products → A16A Other alimentary tract and metabolism products → A16AX Various alimentary tract and metabolism products
Discover more medicines within A16AX18

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
BR	Câmara de Regulação do Mercado de Medicamentos	587921090000301
EE	Ravimiamet	1833689
ES	Centro de información online de medicamentos de la AEMPS	1201496001
FR	Base de données publique des médicaments	66316458
IL	מִשְׂרַד הַבְּרִיאוּת	9026
IT	Agenzia del Farmaco	049177013
LT	Valstybinė vaistų kontrolės tarnyba	1091405
PL	Rejestru Produktów Leczniczych	100444573
RO	Agenția Națională a Medicamentului și a Dispozitivelor Medicale	W67432001